Compare ULCC & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ULCC | KALV |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2017 | 2014 |
| Metric | ULCC | KALV |
|---|---|---|
| Price | $6.05 | $26.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $5.21 | ★ $32.60 |
| AVG Volume (30 Days) | ★ 4.3M | 2.9M |
| Earning Date | 05-05-2026 | 07-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,724,000,000.00 | $50,000,000.00 |
| Revenue This Year | $23.76 | $185.42 |
| Revenue Next Year | $11.48 | $59.23 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $3.02 | $9.83 |
| 52 Week High | $6.66 | $26.98 |
| Indicator | ULCC | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 75.64 |
| Support Level | $4.69 | $14.22 |
| Resistance Level | $6.10 | N/A |
| Average True Range (ATR) | 0.35 | 0.05 |
| MACD | 0.04 | -0.25 |
| Stochastic Oscillator | 90.75 | 98.15 |
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos, and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. The majority of revenue is from Domestic flight follow by International.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.